Xue Peiyu, Zhang Guangjie, Zhang Jie, Ren Li
College of Food Science and Engineering, Jilin University, Changchun 130062, China; School of Biology and Food Engineering, Anyang Institute of Technology, Anyang 455000, China.
School of Biology and Food Engineering, Anyang Institute of Technology, Anyang 455000, China.
Phytomedicine. 2022 May;99:153998. doi: 10.1016/j.phymed.2022.153998. Epub 2022 Feb 18.
Ellagic acid (EA) is a polyphenol compound abundant in berries, walnuts, pecans, pomegranate, cranberries, and other plant foods and exerts a wide array of biological properties. In particular, EA has received considerable research attention in anti-cancer therapy. EA administered alone has been shown to exert effects against human cancers through multiple pathways. In addition, EA may increase tumor sensitivity to chemotherapy and radiotherapy. Namely, EA combination with a relatively low dosage of therapeutic drugs or optimized radiation dose could improve the treatment outcome. More importantly, EA could counteract chemotherapy-related adverse reactions.
This review aims to summarize the in vitro and in vivo experimental evidence of synergism of EA in radiotherapy/chemotherapy for the treatment of cancers. In addition, the preventive effect of EA to counteract chemotherapy-induced toxicity is also discussed.
The searches were performed in the PubMed, Web of Science and Google scholar and introduced the information about the role of EA in cancer treatment.
EA exhibits synergistic effects in radiotherapy/chemotherapy for the treatment of cancers and exerts a great potential in reducing the side effects of chemotherapy and radiotherapy due to its biological activities, such as antioxidant and anti-inflammatory activities.
EA could be a promising drug adjuvant for cancer treatment. In the near future, novel strategies for EA delivery systems that overcome the low EA solubility and bioavailability should be studied further to fully exploit the therapeutic potential of EA.
鞣花酸（EA）是一种多酚化合物，在浆果、核桃、山核桃、石榴、蔓越莓和其他植物性食物中含量丰富，并具有多种生物学特性。特别是，EA在抗癌治疗方面受到了大量的研究关注。单独使用EA已被证明可通过多种途径对人类癌症产生作用。此外，EA可能会增加肿瘤对化疗和放疗的敏感性。也就是说，EA与相对低剂量的治疗药物或优化的辐射剂量联合使用可以改善治疗效果。更重要的是，EA可以抵消化疗相关的不良反应。
本综述旨在总结EA在放疗/化疗协同治疗癌症方面的体外和体内实验证据。此外，还讨论了EA对抵消化疗诱导毒性的预防作用。
在PubMed、科学网和谷歌学术上进行检索，并介绍了EA在癌症治疗中作用的相关信息。
EA在放疗/化疗协同治疗癌症方面具有协同作用，并且由于其抗氧化和抗炎等生物活性，在降低化疗和放疗副作用方面具有巨大潜力。
EA可能是一种有前景的癌症治疗药物佐剂。在不久的将来，应进一步研究克服EA低溶解度和低生物利用度的新型EA递送系统策略，以充分发挥EA的治疗潜力。
